News
Press ReleaseRevive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19
TORONTO, March 25, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained...
Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19
TORONTO, March 24, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as a Scientific Advisor to guide on the Company’s...
Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19
TORONTO, March 20, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza...
Revive Therapeutics Announces Closing of Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, March 18, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a cannabis and...
Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.
TORONTO, March 05, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products, is pleased to announce that, further to its press...
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
TORONTO, Feb. 18, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical...